LABT - Latest News
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $1.1M. Beta to the broader market is 0.00.
The article list below shows the most recent LABT headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent LABT Headlines
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
prnewswire.com - Jul 15, 2026
Nu-3 is a gel formulation of a Bisphosphocin® compound targeting the topical treatment of infected diabetic foot ulcers with low likelihood of produci
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
prnewswire.com - Jul 7, 2026
Company highlights its differentiated Bisphosphocin ® platform and lead clinical candidate Nu-3 as innovative approaches to addressing microbial infec
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D.
prnewswire.com - Jun 25, 2026
Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU program SARASOTA, Fla. , June 25, 2026 /PR
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections
prnewswire.com - Jun 22, 2026
New patent enhances global IP footprint and pipeline expansion opportunities SARASOTA, Fla. , June 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherape
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
prnewswire.com - Jun 16, 2026
SARASOTA, Fla. , June 16, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc.
How News Affects LABT Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track LABT's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked LABT news questions
- What is the latest LABT news headline?
- The most recent LABT headline (Jul 15, 2026) is "Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the LABT news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What LABT news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual LABT options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.